CXCL12 and neoplasm: The infiltration of CAR-T cells to the tumor site is significantly reduced when the chemokine receptor expressed by T cells is not compatible with chemokines secreted by tumor cells, as noted in the case of CXCL-1, CXCL-5, and CXCL-12.